Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes
Authors' conclusion
The pharmacokinetic and pharmacodynamic characteristics of icodec in individuals with T2D support its potential as a once-weekly basal insulin.
Study context
- Population
- Basal insulin-treated individuals with T2D, 18–75 years, BMI 18.0–38.0 kg/m², HbA1c ≤75 mmol/mol [≤9%]
- Participants
- 46 individuals
- Outcome
- Pharmacokinetic and pharmacodynamic properties of once-weekly icodec
- Follow-up
- Steady state
Methodological detailsopen-label, glucose clamps, pharmacokinetic-pharmacodynamic modelling, Glucose effect assessed at steady state in three glucose clamps (target 7.5 mmol/L): 0 to 36, 40 to 64 and 144 to 168 h post-dose
- Open-label
- Glucose clamps
- Pharmacokinetic-pharmacodynamic modelling
- Glucose effect assessed at steady state in three glucose clamps (target 7.5 mmol/L): 0 to 36, 40 to 64 and 144 to 168 h post-dose
Main finding
As reported in the abstract
steady state
Model-predicted icodec steady state attained after
3 to 4 weeks
Model-predicted daily proportions of glucose-lowering effect, days 1 to 7 of the 1-week dosing interval
14.1%, 16.1%, 15.8%, 15.0%, 14.0%, 13.0% and 12.0%
Safety
- Once-weekly icodec was overall safe and well tolerated
Original publication
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. Published 11 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →